Tumoural hypoxia can influence response to radiotherapy and other treatments, and oxygenation status has proved to be a prognostic indicator of the outcome of radiotherapy.1 Therefore, it is important to assess tumour...Tumoural hypoxia can influence response to radiotherapy and other treatments, and oxygenation status has proved to be a prognostic indicator of the outcome of radiotherapy.1 Therefore, it is important to assess tumoural hypoxia and reoxygenation before selection of treatment protocols. During the last two decades, much attention has been paid to noninvasive imaging techniques using radiolabelled markers for the detection of hypoxic cells in solid tumours.2 Technetium （^99mTc） is a very convenient isotope for use with such imaging because it is readily available and suited to routine clinical use.展开更多
Objective To review the current status and progress on nuclear medical molecular imaging of angiogenesis. Data sources A literature search was performed in Medline and PubMed published in English up to May 31, 2012. T...Objective To review the current status and progress on nuclear medical molecular imaging of angiogenesis. Data sources A literature search was performed in Medline and PubMed published in English up to May 31, 2012. The search terms were molecular imaging, nuclear medicine and angiogenesis. Study selection Articles studying molecular imaging of angiogenesis using radionuclide were selected and reviewed. Results Molecular imaging has been used for studying angiogenesis by targeting integrin aVI33, VEGF/VEGFR, and matrix metalloproteinases （MMPs） with radionuclide-labeled tracers. The technology has been shown to be able to assess the angiogenesis status and/or predict the efficacy of anti-angiogenic therapy. Future directions of the research on the molecular imaging of angiogenesis include development of new tracers with better tumor targeting efficacy, desirable pharmacokinetics, and easy translation to clinical applications. Conclusion Advances in molecular imaging of angiogenesis using radioculcide will make the technology a valuable tool for personalized anti-angiogenesis treatment.展开更多
基金This study was sponsored by grants from the National Natural Science Foundation of China(No.30371381)Key Projects Foundation of Department of Science and Technology of Shandong province(No.031050102).
文摘Tumoural hypoxia can influence response to radiotherapy and other treatments, and oxygenation status has proved to be a prognostic indicator of the outcome of radiotherapy.1 Therefore, it is important to assess tumoural hypoxia and reoxygenation before selection of treatment protocols. During the last two decades, much attention has been paid to noninvasive imaging techniques using radiolabelled markers for the detection of hypoxic cells in solid tumours.2 Technetium （^99mTc） is a very convenient isotope for use with such imaging because it is readily available and suited to routine clinical use.
文摘Objective To review the current status and progress on nuclear medical molecular imaging of angiogenesis. Data sources A literature search was performed in Medline and PubMed published in English up to May 31, 2012. The search terms were molecular imaging, nuclear medicine and angiogenesis. Study selection Articles studying molecular imaging of angiogenesis using radionuclide were selected and reviewed. Results Molecular imaging has been used for studying angiogenesis by targeting integrin aVI33, VEGF/VEGFR, and matrix metalloproteinases （MMPs） with radionuclide-labeled tracers. The technology has been shown to be able to assess the angiogenesis status and/or predict the efficacy of anti-angiogenic therapy. Future directions of the research on the molecular imaging of angiogenesis include development of new tracers with better tumor targeting efficacy, desirable pharmacokinetics, and easy translation to clinical applications. Conclusion Advances in molecular imaging of angiogenesis using radioculcide will make the technology a valuable tool for personalized anti-angiogenesis treatment.
